Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Zhao S, Yin C, Zhai Y, Jia Z, Su S, Lu Y, et al. Serum peptidomic screening identified circulating peptide biomarkers predictive for preeclampsia. Front Cardiovasc Med. 2022;9:946433.

Velu PD, Cushman-Vokoun A, Ewalt MD, Feilotter H, Gastier-Foster JM, Goswami RS, et al. Alignment of Fellowship Training with Practice Patterns for Molecular Pathologists: A Report of the Association for Molecular Pathology Training and Education Committee. J Mol Diagn. 2022;24(8):825-840.

Rosenstock JL, Joab TM, DeVita MV, Yang Y, Sharma PD, Bijol V. Oxalate nephropathy: a review. Clin Kidney J. 2022;15(2):194-204.

Haas M, Mirocha J, Amann K, Bajema IM, Barisoni L, Becker JU, et al. Impact of Consensus Definitions on Identification of Glomerular Lesions by Light and Electron Microscopy. Kidney Int Rep. 2022;7(1):78-86.

Kwon O-, Zhang B, Jia D, Zhang L, Wei X, Zhou Z, et al. Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130. Oncogene. 2022;41(9):1309-1323.

Lally L, Narula N, Goodfellow N, Luqmani R, Pisapia D, Spiera RF. Rho Kinase Expression in Giant Cell Arteritis: Validating Phosphorylated Ezrin/Radixin/Moesin Intensity Score to Increase Sensitivity of Temporal Artery Biopsy. J Rheumatol. 2022;49(8):908-912.

Brendel M, Getseva V, Assaad MA, Sigouros M, Sigaras A, Kane T, et al. Weakly-supervised tumor purity prediction from frozen H&E stained slides. EBioMedicine. 2022;80:104067.

Choi SY, Ribeiro CF, Wang Y, Loda M, Plymate SR, Uo T. Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. Biomolecules. 2022;12(11).

Dallimore CA, Quelle M, Désir LL, Sham S, Harshan M, Wahl SJ, et al. Calcifying Pseudoneoplasm of the Neuraxis in the Posterior Fossa: A Case Report and Literature Review. Cureus. 2022;14(1):e21562.

Berchuck JE, Boiarsky D, Silver R, Sunkara R, McClure HM, Tsai HK, et al. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. JCO Precis Oncol. 2022;6:e2200329.